| |
Diabetic group (n = 72)
|
Non-diabetic group (n = 144)
|
t/χ2
|
P value
|
|---|
|
Age (years)
|
52.72 ± 6.23
|
50.08 ± 4.76
|
3.113
|
<0.001
|
|
Family history of BC
|
5.56% (4)
|
4.17% (6)
|
0.458
|
0.647
|
|
Underlying diseases
|
19.44% (14)
|
20.83% (30)
|
0.057
|
0.811
|
|
Ratio of menopause
|
76.39% (55)
|
55.56% (80)
|
8.889
|
0.003
|
|
BMI (Kg/m2)
|
24.68 ± 4.74
|
23.21 ± 3.25
|
2.673
|
0.008
|
|
SBP (mmHg)
|
124.68 ± 10.35
|
125.36 ± 11.23
|
0.430
|
0.667
|
|
DBP (mmHg)
|
78.36 ± 7.93
|
80.57 ± 8.54
|
1.835
|
0.068
|
|
HDL-C (mmol/L)
|
1.21 ± 0.32
|
1.31 ± 0.36
|
1.995
|
0.047
|
|
LDL-C (mmol/L)
|
3.85 ± 0.74
|
3.12 ± 0.65
|
7.425
|
<0.001
|
|
TG (mmol/L)
|
1.32 ± 0.35
|
1.41 ± 0.41
|
1.594
|
0.112
|
|
TC (mmol/L)
|
4.45 ± 0.87
|
3.64 ± 0.68
|
7.498
|
<0.0001
|
|
FPG (mmol/L)
|
8.32 ± 0.73
|
5.27 ± 0.43
|
38.56
|
<0.001
|
|
2hPG (mmol/L)
|
14.68 ± 1.02
|
5.58 ± 0.47
|
89.810
|
<0.001
|
|
HbA1c (%)
|
10.57 ± 2.11
|
5.64 ± 1.57
|
19.320
|
<0.001
|
|
FIns (uU/mL)
|
10.14 ± 3.25
|
5.33 ± 1.87
|
6.954
|
<0.001
|
|
HOMA-IS
|
42.84 ± 14.53
|
60.50 ± 16.29
|
7.779
|
<0.001
|
|
HOMA-IR
|
3.75 ± 1.25
|
1.27 ± 0.50
|
20.750
|
<0.001
|
|
E2 (pg/mL)
|
50.20 ± 11.40
|
23.66 ± 8.63
|
19.080
|
<0.001
|
- Comparisons on family history of BC, underlying diseases and the ratio of menopause between the two groups were measured by χ2 test; BMI, weight (kg)/height (m2); Normal BMI, 18.5–22.9 kg/m2
- Diabetic group, breast cancer patients with type 2 diabetes mellitus; Non-diabetic group, breast cancer patients without type 2 diabetes mellitus
-
BC breast cancer, BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, TG triglyceride, TC total cholesterol, FPG fasting blood glucose, 2hPG 2-hour postprandial blood glucose, HbA1c glycosylated hemoglobin, FIns fasting insulin, HOMA-IR homeostasis model assessment of insulin resistance, HOMA-IS HOMA of β-cell insulin secretion, E
2
estradiol
